Compass Pathways Plc Quick Ratio (CMPS) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Compass Pathways Plc  (NASDAQ: CMPS)

Compass Pathways Plc's Quick Ratio

CMPS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Compass Pathways Plc's Cash & cash equivalent grew by 2.37 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Compass Pathways Plc's Quick Ratio to 1.36, Quick Ratio remained below Compass Pathways Plc average.

Within Major Pharmaceutical Preparations industry 337 other companies have achieved higher Quick Ratio than Compass Pathways Plc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 901 to 1829.

Explain Quick Ratio?
How much Cash & cash equivalents CMPS´s has?
What are CMPS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CMPS Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3
Y / Y Current Liabilities Change 1219.71 % 1093.53 % 365.83 % -25.64 % -21.61 %
Y / Y Cash & cash equivalent Change 138.29 % 95.14 % 79.04 % -9.36 % -10.14 %
Quick Ratio MRQ 1.36 1.18 3.07 5.34 7.55
CMPS's Total Ranking # 1829 # 901 # 2163 # 1494 #
Seq. Current Liabilities Change -11.28 % 141.79 % 440.99 % 13.72 % -19.76 %
Seq. Cash & cash equivalent Change 2.37 % -7 % 210.95 % -19.5 % -16.17 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 338
Healthcare Sector # 602
Overall Market # 1829


Quick Ratio Statistics
High Average Low
69.41 13.63 1.18
(Jun 30 2021)   (Jun 30 2026)




Financial Statements
Compass Pathways Plc's Current Liabilities $ 326 Millions Visit CMPS's Balance sheet
Compass Pathways Plc's Cash & cash equivalent $ 444 Millions Visit CMPS's Balance sheet
Source of CMPS's Sales Visit CMPS's Sales by Geography


Cumulative Compass Pathways Plc's Quick Ratio

CMPS's Quick Ratio for the trailling 12 Months

CMPS Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 593.88 % 331.21 % 85.18 % 2.7 % 24.06 %
Y / Y Cash & cash equivalent TTM Growth 79.03 % 44.51 % 18.86 % -5.32 % -9.32 %
Quick Ratio TTM 1.71 2.16 4.35 7.05 6.63
Total Ranking TTM # 3913 # 3792 # 3040 # 2813 #
Seq. Current Liabilities TTM Growth 52.66 % 142.92 % 102.71 % -7.69 % -5.13 %
Seq. Cash & cash equivalent TTM Growth 20.84 % 20.63 % 25.14 % -1.86 % -2.46 %

Quick ratio ranking by company, industry and sector >> Back to CMPS Financial Strength Comparisons >> Go to Compare CMPS Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q3 2026 to $325.86 millions, cumulative Quick Ratio decreased to 1.71 below the Compass Pathways Plc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Compass Pathways Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3792 to 3913.

Explain Quick Ratio?
How much Cash & cash equivalents CMPS´s has?
What are CMPS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 434
Healthcare Sector # 888
Within the Market # 3913


trailing twelve months Quick Ratio Statistics
High Average Low
27.61 11.56 1.28
(Dec 31 2020)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Rapport Therapeutics Inc   3.68 $ 74.754  Millions$ 20.302  Millions
Seaport Therapeutics Inc   3.60 $ 61.552  Millions$ 17.106  Millions
Cytokinetics Incorporated  3.20 $ 1,130.021  Millions$ 353.419  Millions
Elicio Therapeutics Inc   3.11 $ 30.900  Millions$ 9.930  Millions
Harmony Biosciences Holdings inc   3.02 $ 771.138  Millions$ 254.981  Millions
Phio Pharmaceuticals Corp  2.96 $ 10.609  Millions$ 3.583  Millions
Zevra Therapeutics Inc   2.95 $ 122.148  Millions$ 41.369  Millions
Pyxis Oncology Inc   2.79 $ 55.572  Millions$ 19.942  Millions
Zenas Biopharma Inc   2.78 $ 177.778  Millions$ 64.043  Millions
Ptc Therapeutics inc   2.74 $ 2,127.918  Millions$ 776.076  Millions
Turn Therapeutics Inc   2.71 $ 9.433  Millions$ 3.479  Millions
Beone Medicines Ltd   2.67 $ 5,955.905  Millions$ 2,233.923  Millions
Biohaven Ltd   2.57 $ 161.125  Millions$ 62.767  Millions
Ironwood Pharmaceuticals inc   2.49 $ 86.376  Millions$ 34.733  Millions
Tg Therapeutics Inc   2.43 $ 632.004  Millions$ 260.526  Millions
Adc Therapeutics Sa  2.42 $ 189.204  Millions$ 78.125  Millions
Opko Health Inc   2.37 $ 384.036  Millions$ 162.356  Millions
Pacira Biosciences inc   2.31 $ 295.577  Millions$ 128.209  Millions
Dogwood Therapeutics inc   2.28 $ 4.948  Millions$ 2.174  Millions
Ardelyx inc   2.23 $ 285.338  Millions$ 127.805  Millions
Schrodinger Inc   2.20 $ 366.358  Millions$ 166.292  Millions
Stoke Therapeutics Inc   2.19 $ 107.271  Millions$ 48.977  Millions
Maravai Lifesciences Holdings Inc   2.14 $ 73.023  Millions$ 34.160  Millions
Ernexa Therapeutics Inc   2.13 $ 5.575  Millions$ 2.614  Millions
Madrigal Pharmaceuticals Inc   2.12 $ 962.387  Millions$ 454.244  Millions
Puma Biotechnology Inc   2.09 $ 108.575  Millions$ 51.971  Millions
Corcept Therapeutics Inc  2.09 $ 370.703  Millions$ 177.675  Millions
Dianthus Therapeutics Inc   1.95 $ 55.686  Millions$ 28.515  Millions
Xeris Biopharma Holdings Inc   1.95 $ 262.164  Millions$ 134.479  Millions
Ars Pharmaceuticals Inc   1.95 $ 138.354  Millions$ 70.995  Millions

Date modified: 2026-11-04T15:09:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.